UroGen Pharma Ltd(URGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.99 | Insider Own | 15.09% | Shs Outstand | 48.9M | Perf Week | -3.14% |
| Market Cap | 1.66B | Forward P/E | 11.9 | EPS next Y | 1373.18% | Insider Trans | -1.34% | Shs Float | 41.5M | Perf Month | -17.09% |
| Enterprise Value | 1.74B | PEG | - | EPS next Q | 0.1 | Inst Own | 80.53% | Short Float | 13.51% | Perf Quarter | -16.17% |
| Income | -0.10B | P/S | 8.78 | EPS this Y | 92.99% | Inst Trans | 1.25% | Short Ratio | 6.26 | Perf Half Y | 40.59% |
| Sales | 0.19B | P/B | - | EPS next 5Y | - | ROA | -42.33% | Short Interest | 5.61M | Perf YTD | 44.79% |
| Book/sh | -2.71 | P/C | 15.17 | EPS past 3/5Y | 12.81% 11.57% | ROE | - | 52W High | -33.26% ($50.81) | Perf Year | 62.64% |
| Cash/sh | 2.24 | P/FCF | - | Sales past 3/5Y | 19.49% 56.22% | ROIC | -158.4% | 52W Low | 105.52% ($16.50) | Perf 3Y | 206.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.9% | Gross Margin | 90.85% | Volatility(W/M) | 3.89% 5.35% | Perf 5Y | 108.42% |
| Dividend TTM | - | EV/Sales | 9.24 | Sales Y/Y TTM | 100.27% | Oper. Margin | -35.32% | ATR (14) | 1.88 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.41 | EPS Q/Q | 72.78% | Profit Margin | -51.73% | RSI (14) | 29.97 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.8 | Sales Q/Q | 199.22% | SMA20 | -9.31% ($37.39) | Beta | 1.66 | Target Price | $60 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/4 | SMA50 | -18.02% ($41.36) | Rel Volume | 1.15 | Prev Close | $34.04 |
| Employees | 291 | LT Debt/Eq | - | EPS/Sales Surpr. | -5.66% 14.02% | SMA200 | 9.01% ($31.11) | Avg Volume(3M) | 0.90M | Price | $33.91 |
| IPO | 2017/5/4 | Option/Short | Yes/Yes | Trades | 8974 | Volume | 1,033,099 | Change | -0.38% |
🔬 UroGen Pharma is a US-listed biotech company targeting urological and urothelial cancers. Leveraging its proprietary RTGel drug delivery technology, the company develops and commercializes non-surgical treatments for low-grade cancers of the bladder and upper urinary tract. Expanding launches of approved products and advancing its late-stage clinical pipeline serve as its key growth drivers.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
Next earnings report: November 4
7 days to go.
URGN has a sound balance sheet but weak earning power
Of every $100 in sales, $35.32 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +93.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $878. Peers typically go for $1,648.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +108.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 80.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #119 of 594 in the industry
Based on market cap of $2B.
QURE#118 uniQure NV $2B PER - URGN#119 UroGen Pharma Ltd $2B PER - 
NVAX#120 Novavax Inc $2B PER - 
RARE#121 Ultragenyx Pharmaceutical Inc $2B PER - 
IMCR#122 Immunocore Holdings plc ADR $2B PER - 
FAQ
What kind of company is URGN?
URGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of URGN?
The market cap of URGN is approximately $1.7B, ranking 2,216 within its sector.
What is the 52-week high and low for URGN?
URGN has recorded a 52-week high of $50.81 and a low of $16.50.
